Current and novel agents for the treatment of cytomegalovirus retinitis.

被引：2

作者：

Akerele T. ^{[1
]}

Lightman S. ^{[1
]}

机构：

[1] Department of Clinical Ophthalmology, Institute of Ophthalmology, London

来源：

Drugs in R & D | 1999年 / 2卷 / 5期

关键词：

Ganciclovir; Retinitis; Acquire Immune Deficiency Syndrome; Cidofovir; Foscarnet;

D O I：

10.2165/00126839-199902050-00001

中图分类号：

学科分类号：

摘要：

The incidence of cytomegalovirus (CMV) retinitis appears to be declining with improved treatment protocols for HIV and prophylaxis protocols for other high risk patients. Despite this, CMV retinitis remains a major cause of visual loss in patients who are severely immunocompromised. Treatment options are evolving in the light of viral resistance, new methods of drug delivery, new drugs, and the increased potential for improvement of immune function that modern antiretroviral therapy provides. In this article, we review the changing options available for the management of CMV retinitis and discuss possible therapeutic agents for the future.

引用

页码：289 / 297

页数：8

共 196 条

[1]

Pepose JS(1985)Acquired immune deficiency syndrome: pathogenic mechanisms of ocular disease Ophthalmology 92 472-85

[2]

Holland GN(1988)Retinal and gastrointestinal disease due to cytomegalovirus in patients with the acquired immune deficiency syndrome: prevalence, natural history, and response to ganciclovir therapy Q J Med 67 473-86

[3]

Nestor MS(1998)The HIV Outpatients Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection N Engl J Med 338 853-60

[4]

Jacobson MA(1998)Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients Drugs 56 115-46

[5]

O’Donnell JJ(1993)Prevention of cytomegalovirus disease Semin Respir Infect 8 225-32

[6]

Porteous D(1999)Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplant Haematologica 841 71-9

[7]

Palella FJ(1999)Acyclovir prophylaxis of cytomegalovirus disease in kidney transplant recipients Transpl Proc 31 2335-6

[8]

Delaney KM(1999)Intravenous ganciclovir prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant recients Transpl Int 12 254-60

[9]

Moorman AC(1997)Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Study Group Lancet 350 1729-33

[10]

Noble S(1998)Cytomegalovirus retinitis after cardiac transplantation Am J Ophthalmol 125 104-6

← 1 2 3 4 5 6 7 8 9 10 →